A biotech company is suing Merck & Co. over its easier-to-use version of its blockbuster cancer treatment Keytruda, alleging the pharmaceutical giant violated its intellectual property. Merck knowingly infringed Halozyme Therapeutics Inc.’s patents in crafting a version of Keytruda that …
Source: Claims Journal